Multicenter, Open-label, Dose-escalation Study of SP-420 in Subjects With Transfusion-dependent β-Thalassemia

Trial Profile

Multicenter, Open-label, Dose-escalation Study of SP-420 in Subjects With Transfusion-dependent β-Thalassemia

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs SP 420 (Primary)
  • Indications Beta-thalassaemia
  • Focus Adverse reactions
  • Sponsors Sideris Pharmaceuticals
  • Most Recent Events

    • 01 Dec 2017 Results published in the American Journal of Hematology
    • 28 Sep 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 04 Sep 2015 Planned End Date changed from 1 Jul 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top